We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Low Serum IGF1 Predicts CV Events in RA Women

By LabMedica International staff writers
Posted on 06 Aug 2019
Hypertension is a significant health threat and an independent predictor of cardiovascular (CV) events including coronary heart disease, stroke, heart failure, and dementia in the general population and in rheumatoid arthritis (RA).

Solid biological evidence connects insulin-like growth factor 1 (IGF1) with the regulation of endothelial cell function. More...
Circulating IGF1 is known to induce vasodilation, which contributes to the regulation of arterial blood pressure (BP) and vascular tone. Disturbances in IGF1/ IGF1 receptor (IGF1R) signaling are notable for RA pathology.

Scientists at Sahlgrenska University Hospital (Gothenburg, Sweden) and their colleagues consecutively enrolled 184 female RA patients. All the patients fulfilled the classification criteria for RA and had median disease duration of seven years. The dominating majority (89%) were Rheumatoid factor (RF) and/or Anti–citrullinated protein antibody (ACPA) positive. For serum preparation, the blood was obtained from the cubital vein into vacuum containers and for RNA preparation into PAXgene protection tubes. Serum samples were stored at − 70 °C and PAXtubes in − 20 °C until use.

In RA samples, serum IGF1, total cholesterol (TC), triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured by photometry on Cobas 8000. In the samples from 132 ischemic stroke patients, serum IGF1 was measured with a radio-immune assay. Total mRNA was prepared, complementary DNA was synthesized, and amplification of the gene product was attained on a ViiA7 Real-Time PCR.

The scientists reported a low IGF1 resulted in a higher estimated cardiovascular disease (eCVR) in RA patients (7.2% and 3.3%) and in stroke (9.3% and 7.1%). RA had higher rate for new CVD events at prospective follow-up. Hypertension was the major risk factor associated with low IGF1 in RA and stroke. In hypertension, IGF1 was no longer responsible for intracellular activation and lost its correlation to Insulin receptor substrate 1 (IRS1/2) adaptor proteins. The clustering analysis confirmed that combination of low IGF1 and IRS1/2 with high interleukin-6 (IL6), insulin, and glucose predisposed to high eCVR and emphasized the functional role of serum IGF1.

The authors concluded that low serum IGF1 precedes and predicts development of early CVD events in female RA patients. Hypertension and aberrant IGF1 receptor signaling are highlighted as the important contributors to IGF1-related CVD events. The study was published on July 22, 2019, in the journal BMC Medicine.

Related Links:
Sahlgrenska University Hospital


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.